Loading…
RLYB
Rallybio Corp
NASDAQ· Healthcare· Biotechnology
$16.81+0.30%
Key metrics
- Market cap
- $89.27M
- P/E
- 2.1x
- Forward P/E
- —
- P/B
- 1.8x
- Dividend yield
- —
- EPS
- $7.99
- ROE
- 64.86%
- Profit margin
- 7051.24%
- Revenue growth
- —
- Beta
- -0.86
- 52-week high
- $17.57
- 52-week low
- $3.67
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
- 7
- New Haven, United States
Company description provided by Yahoo Finance.